Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer
Open Access
- 1 January 1997
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 75 (2) , 301-305
Abstract
Two hundred and eleven patients with node-positive stage II and III breast cancer were treated with eight cycles of adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt), with and without tamoxifen. All patients had undergone radical surgery, and 148 patients were treated with post-operative radiotherapy in two randomized studies. The impact of haematological toxicity of CAFt on distant disease-free (DDFS) and overall survival (OS) was recorded. Dose intensity of all given cycles (DI), dose intensity of the two initial cycles (DI2) and total dose (TD) were calculated separately for all chemotherapy drugs and were correlated with DDFS and OS. Patients with a lower leucocyte nadir during the chemotherapy had significantly better DDFS and OS (P = 0.01 and 0.04 respectively). Dose intensity of the two first cycles also correlated significantly with DDFS (P = 0.05) in univariate but not in multivariate analysis, while the leucocyte nadir retained its prognostic value. These results indicate that the leucocyte nadir during the adjuvant chemotherapy is a biological marker of chemotherapy efficacy; this presents the possibility of establishing an optimal dose intensity for each patient. The initial dose intensity of adjuvant chemotherapy also seems to be important in assuring the optimal effect of adjuvant chemotherapy.Keywords
This publication has 28 references indexed in Scilit:
- The importance of dose intensity in chemotherapy of metastatic breast cancer.Journal of Clinical Oncology, 1984
- Adjuvant Systemic Therapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group’s Trials of Cyclophosphamide or CMF in Premenopausal and Tamoxifen in Postmenopausal Patients1984
- A Controlled Trial of Adjuvant Chemotherapy with Melphalan Versus Cyclophosphamide, Methotrexate, and Fluorouracil for Breast Cancer1984
- The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival.1983
- Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial.1983
- Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles.Journal of Clinical Oncology, 1983
- A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapyAmerican Journal of Clinical Oncology, 1982
- Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes. A southwest oncology group studyCancer, 1982
- Combination chemotherapy for breast cancer metastatic to bone marrowCancer, 1981
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981